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Purpose: Bladder cancer is relatively common but early detection techniques such as cystoscopy 
and cytology are somewhat limited. We developed a broadly applicable, platform-independent 
and clinically relevant method based on simple ratios of gene expression to diagnose human 
cancers. In this study, we sought to determine whether this technique could be applied to the 
diagnosis of bladder cancer.
Experimental design: We developed a model for the diagnosis of bladder cancer using 
expression profiling data from 80 normal and tumor bladder tissues to identify statistically 
significant discriminating genes with reciprocal average expression levels in each tissue type. 
The expression levels of select genes were used to calculate individual gene pair expression 
ratios in order to assign diagnosis. The optimal model was examined in two additional published 
microarray data sets and using quantitative RT-PCR in a cohort of 13 frozen benign bladder 
urothelium samples and 13 bladder cancer samples from our institution.
Results: A five-ratio test utilizing six genes proved to be 100% accurate (26 of 26 samples) for 
distinguishing benign from malignant bladder tissue samples (P  10-6).
Conclusions: We have provided a proof of principle study for the use of gene expression ratios 
in the diagnosis of bladder cancer. This technique may ultimately prove to be a useful adjunct 
to cytopathology in screening urine specimens for bladder cancer.
Keywords: bladder cancer, gene expression profiling, and diagnosis
Introduction
The American Cancer Society (www.cancer.org) estimates there were 67,160 new 
cases of bladder cancer in the United States during 2007 with approximately 13,750 
bladder cancer-related deaths during the same period. The risk of developing bladder 
cancer is higher in men (∼1 in 30) than in women (∼1 in 90). Hematuria or changes 
in bladder habits are the most common symptoms associated with bladder cancer. 
However, fewer than 10% of patients with these symptoms actually have bladder 
cancer. Furthermore, many patients with early disease are asymptomatic and are only 
diagnosed at advanced stage when the therapeutic options are limited. Cystoscopy 
is currently the most accurate and sensitive method for bladder cancer diagnosis. 
However, this endoscopic procedure is relatively expensive and is associated with 
discomfort, inconvenience, and other risk. Therefore, it is only indicated in cases 
where clinical suspicion for bladder tumors exists or for surveillance in patients with 
known bladder cancer.
We have developed a simple, effective gene expression-based algorithm to develop 
specific tests for cancer detection, diagnosis, and prognosis.1–6 This algorithm is based Advances and Applications in Bioinformatics and Chemistry 2009:2 18
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on an initial supervised comparison of gene expression data 
between two groups that differ in a chosen cancer-related 
characteristic, such as benign versus malignant. Molecular 
biomarkers discovered are then used to calculate expres-
sion level ratios of select gene pairs that numerically assign 
tested samples to a given diagnostic or prognostic category. 
In this report, we utilized this ‘gene ratio’ algorithm in a 
proof of principle study using gene expression profiling data 
and discarded surgical specimens of malignant and benign 
bladder tissues.
Materials and methods
human tissues
Thirteen sets of matched adjacent benign bladder and 
bladder cancer samples were obtained from the Tumor 
Bank at Brigham and Women’s Hospital. These frozen 
samples were discarded surgical tissues obtained after 
open surgical resection for bladder cancer and confirmed 
histologically by the tumor bank pathologist. Speci-
men identities were rendered anonymous and linked to 
select clinical and pathologic data. Eleven specimens 
were urothelial carcinoma and two were transitional cell 
carcinoma. Ten of the patients were male. Median age was 
67 (range 40–79) years. Studies utilizing human tissues 
were approved by and conducted in accordance with the 
policies of the Institutional Review Board at Brigham and 
Women’s Hospital.
Gene expression profiling data
A total of four global gene expression datasets of bladder 
tissues were used. “Training Set A” consisted of six 
macrodissected normal bladder mucosa samples from 
patients undergoing bladder surgery for benign causes 
and 19 malignant bladder samples.7 “Training Set B” 
consisted of nine benign biopsies of normal bladder mucosa 
and 46 malignant bladder tissues samples (accessible at NCBI 
GEO database with accession number GSE3167).8 Training 
sets A and B were obtained using Affymetrix high-density 
oligonucleotide microarrays with probe sets representing 
approximately 22,000 genes. “Test Set A” (ie, combination 
of GSE88 and GSE89) consisted of 66 unique bladder tumors 
without matched normal tissue.9 These data were obtained 
using Affymetrix high-density oligonucleotide microarrays 
with probe sets representing approximately 5,600 genes. 
For these three datasets, Affymetrix .cel files were used to 
obtain gene hybridization intensities, which were scaled to a 
“target intensity” of 100 using Affymetrix Microarray Suite 
v.5.0. “Test Set B” was obtained from the supplemental 
files of a recently published manuscript.10 This data set 
consisted of 157 samples composed of 48 histological normal 
urothelium samples obtained at distant sites from the bladder 
tumors resected by cystectomy or cystoprostatectomy and 
109 bladder tumor samples, taken from 105 patients. There 
were several redundant samples and more than one microar-
ray performed on each tissue, which reduced the number of 
unique samples to 39 benign bladder and 91 bladder tumors. 
Because Affymetrix. cel files were not available for this 
dataset, we used the values obtained by the authors analysis 
via Affymetrix Microarray Suite v.5.0 with a scaled “target 
intensity” of 500.
Real-time quantitative RT-PCR
Real-time quantitative reverse transcription-polymerase 
chain reaction (RT-PCR) was performed as described using 
2 µg of total RNA.3 Forward and reverse RT-PCR primers 
(synthesized by Invitrogen Life Technologies, Carlsbad, 
CA) were designed to span large introns (800 bp if 
possible) or to be positioned on the exon/exon junction. 
Primers used at a final concentration of 800 nM in the PCR 
reaction mixture were as follows (forward and reverse, 
respectively): SPARCL1 (5’-AGGAGTGTGACCCCAA-
CAAG-3’ and 5’-CAGAGGAGGATGCTGGAAAG-3’), 
MYH11 (5’-CACAGGAAACTTCGCAGTGA-3’ and 
5_-GAGTGTCCGTTTCCTCCTCA-3’), FHL1 (5’-GAAGT-
GTGCTGGATGCAAGA-3’ and 5_-CCAGATTCACGGAG-
CATTTT-3’), MIF (5’-CCGGACAGGGTCTACATCA-3’ and 
5’-GGCGGGCCTAGAACACAG-3’), H2AFZ (5’-GCTGGT-
GGTGGTGTCATTC-3’ and 5’-CTGGAATCACCAACACT-
GGA-3’), and RPN2 (5’-CACTTTTGCTCCTAGCACGA-3’ 
and 5’-CAGCCAGAAACGTCACACTG-3’). PCR amplification 
of cDNA was performed using a Stratagene MX3000P 
machine and default thermal cycling parameters. No-template 
(ie, negative) controls that contained water instead of tem-
plate were run in multiple wells on every reaction plate. An 
automatically calculated melting point disassociation curve 
generated after every assay was examined to ensure the 
presence of a single PCR species and the lack of primer–
dimer formation in each well. The comparative CT equation 
(Applied Biosystems) describes the exponential nature of 
PCR-based amplification and was used, with minor modifica-
tions, to obtain quantitative values for gene expression ratios 
in all samples. The “CT” term stands for the fractional PCR 
cycle at which the quantity of the amplified product reaches 
a pre-determined threshold. The comparative CT equation 
states that the expression level of a gene in a given sample, 
normalized within the sample to an endogenous reference Advances and Applications in Bioinformatics and Chemistry 2009:2 19
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gene, and relative to the expression level of the same gene in 
another sample (ie, an arbitrarily chosen “calibrator sample”) 
can be represented as: 2-∆∆CT where ∆∆CT = [∆CT(sample “x”)]-
[∆CT(calibrator sample)] and ∆CT = [CT(target gene)]-[CT(reference gene)]. Cal-
culation of an expression ratio using data from two rationally 
selected genes in any single sample negates the need for a 
calibrator sample and a reference gene to standardize when 
using different amounts of starting template. Therefore, to 
form expression ratios of two genes in a single sample, we 
simply presented the expression level of one gene relative 
to the expression level of the other gene. In this case, the 
∆∆CT value in the comparative CT equation was expressed 
as [CT(gene 1) – CT(gene 2)].
Data and statistical analysis
The selection of predictor genes was performed essentially as 
previously described using standard statistical techniques.1–5 
Essentially, we used a two-sided Student’s (parametric) t-test 
for pair-wise comparisons of average gene expression levels 
of all genes represented on the microarrays of both training 
sets to identify those differentially expressed in a statistically 
significant manner (P  0.01) between benign and malignant 
bladder. (Although Training Sets A and B were from the 
same platform, these data were considered separately for 
gene discovery purposes to minimize variability and account 
for potential site-specific confounders.) To further reduce the 
risk of false positives, we chose for additional consideration 
those genes with a 2-fold difference in average expression 
levels and an average gene expression level 600 in at least 
one of the two subsets in both Training Set A and Training 
Set B. The SAM algorithm11 was used to estimate the false 
discovery rate.
Data from multiple highly accurate gene expression ratios 
were combined as described previously3,6 by calculating the 
geometric mean (ie, “combined score”), (R1R2R3)1/3, where 
Ri represents a single ratio value. This is equivalent to the 
average of [log2(R1), log2(R2), log2(R3)], and has the effect 
of giving equal weight to ratio fold-changes of identical mag-
nitude but opposite direction. The classification accuracy of 
the model was assessed using an exact one-sample binomial 
test. The P values are reported under the null hypothesis of 
diagnosis randomly assigned with equal probability of 0.5 
based on one-sided tests in order to reject lower levels of 
accuracy. The 95% confidence interval (CI) for proportions 
is based on the exact binomial distribution. All calculations 
and statistical comparisons were generated using S-PLUS,12 
except the exact binomial procedures that were computed 
using Stata 7 (StataCorp, College Station, TX).
Results
Identification of molecular markers  
in bladder cancer and prediction  
of diagnosis using gene expression ratios
The expression profiles of bladder tumors and normal 
urothelial tissues from Training Set A were compared to 
identify 22 differentially expressed candidate diagnostic 
genes that fit the filtering criteria (Table 1). The false 
discovery rate (FDR) associated with these genes was 13%, 
as calculated using the SAM algorithm.11 All of these genes 
were also statistically significantly differentially expressed in 
Training Set B with a similar minimum two-fold difference in 
means (Table 1). Six of these genes with the lowest P values 
were chosen for further analysis: SPARCL1, MYH11, and 
FHL1 (overexpressed in adjacent nontumorous bladder 
specimens) and MIF, H2AFZ, and RPN2 (overexpressed in 
bladder tumor specimens).
Next, multiple expression ratios of these genes were 
evaluated as to whether they could accurately classify the 
80 samples Training Sets A and B combined. Nine possible 
expression ratios were calculated per sample by dividing 
the expression value of each of the three genes expressed 
at relatively higher levels in the benign bladder samples by 
the expression value of each of the three genes expressed at 
relatively higher levels in the bladder tumors. Samples with 
ratio values 1 were predicted to be “benign” and those 
with ratio values 1 were predicted to be “malignant”. 
These nine individual ratios were found to be accurate (range 
84%–94%; Table 2) in distinguishing benign from malignant 
bladder. The geometric mean of the combination of the five 
individual pair ratios that were at least 90% accurate from 
Table 2 (SPARCL1/MIF, SPARCL1/RPN2, MYH11/RPN2, 
FHL1/MIF, FHL1/RPN2) was calculated. This test was 
highly accurate (73/80, 91%; 95% CI 86%–100%, P  10-6) 
in the combined training sets. Importantly, this test was 
highly accurate in diagnosing tumors (61/65, 94%) but was 
slightly less accurate in the benign bladder subset (12/15, 
80%) perhaps due to small sample size considerations and/or 
contamination by adjacent microscopic tumor elements.
This five-ratio test was then examined in the indepen-
dent test sets. High diagnostic sensitivity was maintained 
in Test Set A (98%, 65/66, 95% CI 92%–100%, P  10-6). 
For Test Set B, when using all the available data (include 
duplicated samples), the sensitivity (85%, 86/109, 95% CI 
78%–90%, 133/157) was significantly (P  10-6) high with 
nearly all benign samples called correctly (98%, 47/48). 
When the duplicated samples and possible histologically Advances and Applications in Bioinformatics and Chemistry 2009:2 20
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misdiagnosed samples (ie, samples that were clustered 
with the opposite histologic classification by unsupervised 
clustering analysis in the original analysis10) were excluded 
from analysis, the five-ratio test could diagnose the remain-
ing 36 benign bladder and 81 bladder tumor samples with 
moderately higher (91%, 84%–95%, 106/117, P  10-6) 
accuracy (or 70/81 for tumor and 36/36 for normal).
Validation of expression level ratios 
as a diagnostic tool in bladder cancer
The five-ratio test was then examined in an independent set 
of 13 matched benign bladder urothelium samples and blad-
der cancer samples (n = 26 samples total) using quantitative 
RT-PCR (Figure 1). The five-ratio diagnostic test was 100% 
accurate (26/26, 95% CI 87%–100%, P  10-6) in classifying 
Table 2 Accuracy of all ratio combinations in predicting tumor 
diagnosis in training sets A and B combined
SPARCL1 MYH11 FHL1
MiF 91% (73/80) 89% (71/80) 90% (72/80)
h2AFZ 84% (67/80) 84% (67/80) 89% (71/80)
RPn2 91% (73/80) 94% (75/80) 90% (72/80)
Notes: Six diagnostic genes were identified in a training set of samples as described 
in the text. A total of nine possible expression ratios (column/row intersection) 
were calculated where both genes used to form the ratio possessed inversely cor-
related expression levels in both tissue types. Predictions are stated as the fraction 
diagnosed correctly.
benign
malignant
G
e
o
m
e
t
r
i
c
 
M
e
a
n
100
10
1
0.1
0.01
0.001
Figure 1 Verification of expression level ratios as a diagnostic tool in bladder cancer. 
Quantitative RT-PCR was used to obtain gene expression levels for the six bladder 
cancer diagnostic genes and calculate the geometric mean of the five-ratio diagnostic 
test (sPARCL1/MiF,  sPARCL1/RPn2, MYh11/RPn2, FhL1/MiF, FhL1/RPn2) in frozen 
samples of benign bladder urothelium (n = 13) and bladder cancer (n = 13). This test 
identified 26 of 26 samples and did not result in any false-negatives. Note that the 
y-axis is in log scale.
these samples (13/13, 95% CI 75%–100%, P = 0.00012 for 
each subset).
Discussion
To improve the diagnostic accuracy of cytology, we explored 
the feasibility of developing a genomic-based diagnostic 
test for bladder cancer that would use quantitative RT-PCR 
for data acquisition. The high accuracy (100%) of our test 
in surgical samples is encouraging in this limited proof of 
principle study, but a prospective collection of additional 
larger numbers of tissue specimens will be necessary before 
determining whether this approach should be used in a clini-
cal setting. Because of the relatively small quantity of RNA 
needed, it is interesting to speculate that this approach would 
support sample attainment using urine samples, considering 
that sufficient mRNA quantity and quality can be isolated 
from bladder washing even for stringent applications such 
as microarray analysis.13 One possible confounder is the 
relatively small number of malignant cells in voided urine 
from bladder cancer patients and the presence of other non-
tumor cell types. Encouragingly, these issue have not proved 
insurmountable in similar applications such as the use of 
gene expression levels of relatively rare cells to diagnosis 
malignant pleural effusions.14
The mechanistic role in carcinogenesis of the diagnostic 
genes we discovered (if any) is not immediately clear by 
examining their known functions. To our knowledge, 
only two of these six genes have been reported to be 
differentially expressed in human cancer tissues. SPARCL1 
is widely expressed in human normal or nonneoplastic 
diseased tissues.15 In contrast, its expression is strongly 
downregulated in most neoplastic cells and tissues15 con-
sistent with our findings. MIF is upregulated in multiple 
human cancers including breast cancer,16 prostate cancer,17 
and nonsmall cell lung cancer.18 The remaining genes 
(eg, MYH11, FHL1, H2AFZ, and RPN2) are not well 
studied. None of the diagnostic genes we identified in this 
study were found in the original analysis of the training 
set samples, perhaps due to the fact that these investigators 
were primarily interested in elucidating genes associated 
with metastatic potential.
Large-scale expression profiling using microarrays is 
ideally suited for use as a gene discovery tool and can also 
aid in the development and validation of predictive models 
as in our analysis of the test set of samples. However, 
microarray technology has limited use in clinical scenarios 
due to the complexity of current bioinformatics tools19 
and the reproducibility, or lack thereof, of measured gene Advances and Applications in Bioinformatics and Chemistry 2009:2
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expression levels.20 On the other hand, quantitative RT-PCR 
is widely considered to be more accurate (and subject to 
less variability) than microarray analysis at the current 
time. Since gene-ratio based tests can utilize quantitative 
RT-PCR for data acquisition, where as other equally accu-
rate bioinformatics models are unproven on this platform, it 
logically follows that the gene ratio technique will provide 
a clear advantage to clinical use.
In summary, we provide evidence that gene expression 
ratio-based cancer classification can be used to distinguish 
bladder cancer from normal bladder tissues in this pilot study 
similar to other cancers2–6 including prostate cancer.1 Specifi-
cally, we found that a five-ratio combination (SPARCL1/
MIF, SPARCL1/RPN2, MYH11/RPN2, FHL1/MIF, FHL1/
RPN2) consisting of six genes was capable of distinguishing 
malignant from nonmalignant bladder tissues with 100% 
accuracy in surgical specimens. These data provide evidence 
to warrant additional study by multiple investigators to 
assess more thoroughly the efficacy of this technique in the 
diagnosis of bladder cancer.
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